BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
+$6.97B
(-1.5%)
Cap. Flow
-$277M
Cap. Flow
% of AUM
-3.98%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
43
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $419M | 6.01% | 9,463,400 -313,128 | -3% | -$13.8M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $335M | 4.81% | 1,158,126 -18,010 | -2% | -$5.21M |
|
3
argenx
ARGX
$43.6B
| $332M | 4.76% | 919,346 -14,457 | -2% | -$5.22M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $303M | 4.35% | 2,855,146 +10,841 | +0.4% | +$1.15M |
|
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $192M | 2.75% | 956,762 -101,424 | -10% | -$20.3M |
|
6
Moderna
MRNA
$9.37B
| $184M | 2.65% | 1,559,801 -17,550 | -1% | -$2.08M |
|
7
Incyte
INCY
$16.5B
| $183M | 2.62% | 2,744,277 -29,100 | -1% | -$1.94M |
|
8
Intuitive Surgical
ISRG
$170B
| $168M | 2.42% | 898,092 -11,256 | -1% | -$2.11M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $155M | 2.22% | 3,329,279 -20,100 | -0.6% | -$935K |
|
|
AXNX
10
DELISTED
Axonics, Inc. Common Stock
AXNX
| $154M | 2.22% | 2,193,200 -120,652 | -5% | -$8.5M |
|
11
Abbott
ABT
$231B
| $152M | 2.18% | 1,569,851 -3,956 | -0.3% | -$383K |
|
12
UnitedHealth
UNH
$281B
| $150M | 2.15% | 296,754 -5,290 | -2% | -$2.67M |
|
13
Boston Scientific
BSX
$156B
| $147M | 2.11% | 3,804,047 -46,124 | -1% | -$1.79M |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $116M | 1.67% | 2,970,678 -2,500 | -0.1% | -$97.9K |
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $115M | 1.65% | 4,058,792 -4,000 | -0.1% | -$113K |
|
16
Jazz Pharmaceuticals
JAZZ
$7.75B
| $110M | 1.58% | 823,839 -94,068 | -10% | -$12.5M |
|
|
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
| $106M | 1.52% | 5,912,639 -7,000 | -0.1% | -$126K |
|
18
Arvinas
ARVN
$568M
| $97.5M | 1.4% | 2,190,762 +66,486 | +3% | +$2.96M |
|
19
Stryker
SYK
$150B
| $96.6M | 1.39% | 476,932 -702 | -0.1% | -$142K |
|
20
Danaher
DHR
$147B
| $94.9M | 1.36% | 367,435 +3,399 | +0.9% | +$878K |
|
21
Relay Therapeutics
RLAY
$619M
| $94.1M | 1.35% | 4,204,820 +172,558 | +4% | +$3.86M |
|
|
22
Revolution Medicines
RVMD
$7.1B
| $92.3M | 1.32% | 4,680,162 +1,296,900 | +38% | +$25.6M |
|
23
Elevance Health
ELV
$71.8B
| $92M | 1.32% | 202,492 -6,008 | -3% | -$2.73M |
|
24
Insulet
PODD
$23.9B
| $85.8M | 1.23% | 373,953 -12,382 | -3% | -$2.84M |
|
25
Edwards Lifesciences
EW
$47.8B
| $84.8M | 1.22% | 1,025,715 +15,088 | +1% | +$1.25M |
|